SomaLogic gains on upbeat 2022 revenue forecast
04/02/2022 18:44
** Shares of diagnostic company SLGC.O rise 3.8% to $8.74
** SLGC says it expects 2022 revenue in range of about $105
mln to $110 mln, above Refinitiv IBES estimates of $103.5 mln
urn:newsml:reuters.com:*:nGNX6lF37r
** SLGC, which has 'proteomics' platform designed to measure
blood proteins and potentially help identify disease markers,
had announced partnership with Illumina ILMN.O in Jan
** SLGC's efforts in diversifying its offerings coupled with
increasing demand for proteomics services implies an "incredibly
bright" future for company - CEO
** Including session moves, SLGC fell 14.7% since it went
public in September through business combination with blank-
check firm CM Life Sciences II Inc
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))
Recent news on Somalogic
See all newsBrief: Somalogic Stockholders Vote To Approve Standard Biotools Transaction At Special Meeting
Brief: Madryn Asset Management Demands Somalogic’S Board Address Repeated, Unprecedented Adjournments Of Tainted Special Meeting
Brief: Madryn Asset Management Says It Urges All Somalogic Shareholders To Oppose Transaction With Standard Biotools
Brief: Madryn Asset Management Urges Shareholders To Vote “Against” The Proposed Merger And Allow Somalogic To Pursue Value-Enhancing Alternatives
Brief: Somalogic Board Reiterates Value-Maximizing Transaction With Standard Biotools Is In Best Interests Of All Stockholders